Company seeks long-term sustainability in its operations
Hemofarm, the regional pharmaceutical leader that last year produced a record-breaking 308 million packages of finished products and more than 7.1 billion units in its plants, is marking 63 years of successful business. The firm’s motto, ‘Caring for People’s Health. Caring for a Sustainable Future’, underscores its commitment to health and promoting humanity.
‘We started 2023 with an even more ambitious plan to produce over 315 million packages of finished products, which would represent a new production record. We compete with ourselves and everything we achieve; we achieve as a team. In addition to the record production that we achieve year after year, we have remained regional market leaders in extremely challenging times. We continued to invest in people, processes, innovations in production and expansion of the portfolio with the state-of-the-art medicines’, said Hemofarm CEO Ronald Seeliger.
Over the course of the previous year the company also restructured its product portfolio, strengthening older, well-known brands such as Rinasek, Febricet, and Midol. Hemofarm bolstered its cardiology business, the largest segment of its pharmaceutical portfolio, by adding two modern antithrombotic drugs. In 2022 the company also registered four generic cancer drugs and a biosimilar to enter the oncology field, the fastest growing segment of Serbia’s drug market.
Certificates of appreciation were presented to the Hemofarm Foundation and Hemofarm d.o.o. Banja Luka, with both entities celebrating 30 years of caring for people’s health, whilst the Vršac Injectables Plant was recognised for 20 years of successful work.
Hemofarm was founded in Vršac, Serbia, on 1 June 1960. Starting with no more than 30 staff at its inception, 63 years later the company has grown to become a regional leader, employing some 4,000 people across four continents. In addition to its Serbian sites in Vršac, Šabac, and Dubovac, Hemofarm also produces high-quality pharmaceuticals in Banja Luka (Bosnia and Herzegovina) and Podgorica (Montenegro). Since 2006, when it joined the STADA Group, Hemofarm has invested 420 million euros in modernizing its plants, equipment, and facilities.
